Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the indication is limited to PD-L1-positive disease.
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the indication is limited to PD-L1-positive disease.
